Pfizer Inc. (NYSE:PFE) Shares Sold by Evanson Asset Management LLC

Evanson Asset Management LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 13.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 16,048 shares of the biopharmaceutical company’s stock after selling 2,523 shares during the period. Evanson Asset Management LLC’s holdings in Pfizer were worth $462,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in PFE. Worth Asset Management LLC purchased a new stake in shares of Pfizer during the first quarter worth about $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the 3rd quarter worth $30,000. Sanctuary Wealth Management L.L.C. purchased a new stake in shares of Pfizer in the fourth quarter valued at $50,000. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Truist Financial decreased their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Performance

PFE traded down $0.03 on Thursday, hitting $27.75. 39,620,254 shares of the company’s stock were exchanged, compared to its average volume of 43,835,094. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a fifty day moving average of $27.46 and a two-hundred day moving average of $29.46. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22. The firm has a market cap of $157.14 billion, a PE ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the firm posted $1.14 EPS. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.